Skip to content
DataLookout
Menu

NCT07554339

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 23 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 115 → 119 locations
    • Trial sites expanded: 107 → 115 locations
  2. Minor Study sites: 107 to 115
  3. Minor Trial sites expanded: 103 → 107 locations
  4. Minor Trial sites expanded: 98 → 103 locations
  5. Minor Trial sites expanded: 95 → 98 locations
  6. Minor Trial sites expanded: 91 → 95 locations
  7. Minor Trial sites expanded: 84 → 91 locations
    • Trial sites expanded: 80 → 84 locations
  8. Minor Study sites: 80 to 84
  9. Notable Eligibility criteria expanded, about 20 words
    • Trial sites expanded: 73 → 80 locations
    • Secondary endpoints: details revised at 7 of 9 entries
  10. Minor Trial sites expanded: 65 → 73 locationsv14
  11. Minor Study sites: 63 to 65v13
  12. Minor Trial sites expanded: 59 → 63 locationsv12
  13. Minor Trial sites expanded: 56 → 59 locationsv11
  14. Minor Trial sites expanded: 53 → 56 locationsv10
  15. Minor Study sites: 52 to 53v9
  16. Minor Study sites: 50 to 52v8
  17. Minor Trial sites expanded: 35 → 50 locationsv7
  18. Minor Study sites: 33 to 35v6
  19. Minor Trial sites expanded: 25 → 33 locations
    • Trial sites expanded: 16 → 25 locations
    v5
  20. Minor Study sites: 16 to 25v4
  21. Minor Trial sites expanded: 5 → 16 locations
    • Start date changed from estimate of Jun 5, 2026 to Jun 18, 2026
    v3
  22. Notable Recruitment opened
    • Trial sites expanded: 0 → 5 locations
    v2
  23. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: Up to approximately 6 years

Secondary (9)

Overall Survival (OS)
Number of Participants Who Experience an Adverse Events (AEs)
Number of Participants Who Discontinue Study Treatment Due to an AE
Objective Response Rate (ORR)
Duration of Response (DOR)
Show 4 moreShow less
Distant Metastasis-Free Survival (DMFS)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) (Items 29 & 30) Combined Score
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Combined Score
Change from Baseline in Role Functioning (EORTC QLQ-C30 Items 6 & 7) Combined Score

Arms and interventions

Calderasib + DurvalumabExperimental

Participants will receive calderasib and durvalumab.

Placebo + DurvalumabActive comparator

Participants will receive placebo to calderasib and durvalumab.

Drugs: Calderasib

Biologicals: Durvalumab

Other: Placebo to MK-1084

Sites

119 sites in 18 countries

China 28, Ukraine 14, Turkey (Türkiye) 9, United States 8, Spain 7, Argentina 6, Japan 6, South Korea 6, Brazil 5, Greece 5, Taiwan 5, Australia 4, Italy 4, Netherlands 4, Germany 3, France 2, United Kingdom 2, Poland 1